BSIC | Bocconi Students Investment Club
  • Articles
    • Markets
    • Corporate Finance
  • The Team
    • Members
    • Alumni
  • About Us
  • Gallery
  • Join Us
  • Contacts
  • Subscribe
  • Collaborations

novartis

Corporate Finance

Headed for Redemption? GSK and its Strategic Turnaround

Download PDF Introduction Facing rising scrutiny from American activist investors, GlaxoSmithKline (GSK), Britain’s second-largest pharmaceutical company, is undertaking a major strategic shift. By spinning off its consumer healthcare division, and recently acquiring Sierra Oncology for $1.9bn, which is about to introduce a new blood cancer treatment to the market, GSK Read more…

By BSIC, 3 years1 May 2022 ago
Corporate Finance

Big pharma in the age of COVID-19

Download PDF Introduction The pharmaceuticals sector has been the center of attention lately for the successful vaccines trial that finally gave some hope of recovery, even though it wasn’t without controversies. However, a lot more has been going on in the industry that might change the reputation that the industry Read more…

By BSIC, 4 years6 December 2020 ago
Corporate Finance Old Articles

Novartis-AveXis: an $8.7bn gene repair

Novartis AG (SIX: NOVN) – market cap as of 20/04/2018: CHF204.12bn AveXis Inc (NASDAQ: AVXS) – market cap as of 20/04/2018: $7.62bn Introduction On April 9, Novartis submitted an offer to acquire all the shares of the American gene therapy group AveXis. The Swiss drugmaker offered an 88% premium adding Read more…

By BSIC, 7 years22 April 2018 ago
Corporate Finance Old Articles

Novartis places a $3.9bn bet on radio pharmaceuticals

Novartis AG (NYSE:NVS) – market cap as of 04/11/2017: $219bn Advanced Accelerator Applications SA (NASDAQ:AAAP) – market cap as of 04/11/2017: $3.56bn Introduction On October 30, 2017, Novartis announced its intention to make a tender offer for 100% of the share capital of Advanced Accelerator Applications, for a total consideration Read more…

By BSIC, 8 years5 November 2017 ago
Corporate Finance Debt Deals Equity Deals M&A Deals Old Articles

Teva and Mylan : The Plot Thickens…

Teva Pharmaceutical Industries ; Market Cap (as of 25/04/2015): $62,67bn Mylan Pharmaceuticals ; Market Cap (as of 25/04/2015): $36,06bn   Introduction In the healthcare industry, the saying “eat or be eaten” no longer applies. Instead, the adage of “make a bid or wait for an offer” would be more appropriate Read more…

By BSIC, 10 years25 April 2015 ago
Corporate Finance M&A Deals Old Articles

Pharma’s Big Deal of the Year: Shire acquires ViroPharma

Shire PLC Market Cap (as of 15/11/13): £15.7bn ViroPharma Inc. Market Cap (as of 15/11/13): $3.3bn Monday, November 11th brought about the much rumored king-size deal of the year in the pharmaceutical sector: Shire PLC of Ireland acquired ViroPharma Inc., a US-based niche company focused on rare diseases, for a Read more…

By BSIC, 12 years16 November 2013 ago

[instagram-feed]

Follow Us

  • Disclaimer
  • About Us
  • Join Us
  • Contacts
  • Subscribe
  • Privacy Policy
  • Cookie Policy
Hestia | Developed by ThemeIsle